Galyan Bio

Orally administered treatments for neurodegenerative diseases


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

 

Implementing the impossible
GALYAN BIO:
FAST FACTS

No one wants to grow old, but it is inevitable -- the side effects of it shouldn’t be. Our bodies change, fall apart and become more susceptible to disease.

Galyan Bio is on a mission to change that.

Implementing the impossible
A HORRIFYING PROBLEM

That affects every one of us or someone we know and love 

Neurodegenerative diseases are horrible, difficult to combat and leave patients with little recourse. It is estimated that more than 6 million Americans suffer from Alzheimer’s. By 2050, this number is projected to rise to nearly 13 million. In 2021, Alzheimer’s and other dementias will cost the nation $355 billion. By 2050, these costs could rise as high as $1.1 trillion.

We need solutions, and we need them fast.

Part of the challenge is that, as we age, our ability to break down and remove misfolded proteins gradually diminishes. Think of misfolded proteins as garbage in cells -- they disrupt their functions and finally cause them to die. Now think about what happens when garbage isn't removed from any other area of life, and you'll begin to see how problematic this becomes.

What we really need is a way to help cells remove these proteins, which would not only slow down aging but also improve motor functions and reduce cancer risk.

This, in turn, could subsequently help treat neurodegenerative diseases like Alzheimer’s. As we have demonstrated that our compounds reduce pathological tau and at the same time also tackle amyloid ß.

Implementing the impossible
TRACTION & ACCOMPLISHMENTS

Proof of Concept
Galyan Bio is developing the real deal. We are so confident in our compounds that we have proudly demonstrated in vivo proof of concept data showing dramatic improvement of median life expectancy of C. elegans and improved motor function in aged animals.

Pharmaceutical Support
We are currently in discussions with a pharmaceutical company for licensing our Huntington disease compounds, with the goal of fighting this horrific and deadly disease.

Patents
We filed two matter of composition patents in 2020 and a mode of action patent in 2021.

Partnerships
We are collaborating with Thermally Targeted Therapeutics, Inc., a spin-out of the University of Mississippi. We also have an ongoing collaboration with Bicoll GmbH.

Implementing the impossible
GALYAN BIO IS THE SOLUTION

We want to change the future of aging and reduce neurodegenerative diseases

Galyan Bio is on a mission to overcome these problems.

We started in 2015 and worked hard to demonstrate our potential by screening compounds in silico for a Huntington disease target. We were awarded a research grant from the European Union in 2018; we then demonstrated that, in the R6/2 Huntington disease model, our predecessor lead compound (GLYN122) could improve significantly motor symptoms.

We later relocated to the United States and founded Galyan Bio to continue our mission and our research. We have since optimized our compounds and, in 2021, we have demonstrated that GLYN345 improves median survival in the animal model of aging.

We achieve this success with unique small molecules that remove harmful proteins without affecting naturally occurring proteins in cells, which are important for their normal functioning and thus survival of these cells. The compounds bind to misfolded proteins and trigger their degradation by the cells' own protein garbage removal systems, mainly autophagy.

Implementing the impossible
WHY WE’LL LEAD

Survive Longer, Live Better
GLYN345 (our lead compound) improves median survival in vivo and the motility of aged animals. As a result, the lead compound has a healthy aging effect.

Improve Quality of Life
Brain aging is one of the greatest challenges we face. We can work out, eat healthy and do all the right things... but if the brain continues to age/fall apart, the rest of the body will do the same.

Thus, we are particularly proud of the way in which our compound overcomes the blood brain barrier and protects also the brain from aging. It is, by far, one of the most important properties of the compound.

Prevent Cancer Like Never Before
Looking ahead, Galyan Bio is proud to have a further optimized compound (GLYN441) of the same series that demonstrated a cancer-killing effect in two different glioblastoma (brain cancer) cell lines. As a result, we are excited to offer a treatment that protects the body and brain from aging while reducing the risk of developing cancer with aging.

Implementing the impossible
MEET THE TEAM

Marius Galyan, MD | CEO
Vast expertise in clinical research and in biopharmaceutical development

 

Sarah Arbe-Barnes, PhD | CBO
Over 25 years of experience in drug development 

 

Chris Lehman, MBA | CFO
Over 20 years financial and transactional experience in the biotechnology industry

 

Duncan Judd | Drug Discovery
Responsible for the medical chemistry strategy

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.